Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (BCRP)-mediated resistance to therapeutic agents

Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (BCRP)-mediated resistance to therapeutic agents

US Patent 7879868 · Granted Feb 1, 2011

Estimated economic value: $10,810,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Altertoxin II as a selective inhibitor of Ewing family of tumor cells2020
Combination comprising a signal transduction inhibitor and an epothilone derivat2010
Compositions and methods for sensitizing and inhibiting growth of human tumor ce2008
4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives2008
7H-pyrrolo[2,3-d]pyrimidine derivatives2008
4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives2007
Compositions and methods for sensitizing and inhibiting growth of human tumor ce2006
Compositions and methods for sensitizing and inhibiting growth of human tumor ce2004
Phthalazines with angiogenesis inhibiting activity2004
Pyrido-, pyrimido-, pyridazo- and pyrazo- pyridazines having angiogenesis inhibi2003
Phthalazines with angiogenesis inhibiting activity2001
Pyrimidine derivatives and processes for the preparation thereof2001